Researchers say the Alzheimer’s vaccine could be tested on humans within 3-5 years.
Study co-author Prof. Nikolai Petrovsky, of Flinders University School of Medicine in Australia, and colleagues reveal how a vaccine combination generates antibodies that target beta-amyloid and tau proteins in the brain – both of which are considered hallmarks ofAlzheimer’s disease.
Beta-amyloid is known to accumulate in the brains of people with Alzheimer’s, forming plaques, while the tau protein forms tangles. Plaques and tangles are believed to disrupt signaling between nerve cells and contribute to nerve cell death.
To continue reading click link below:
http://www.medicalnewstoday.com/articles/311731.php